The CHMP has recommended granting a conditional marketing authorization to the drug under the brand name, Veklury, for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.Alexion intends to file for the approval of the SC formulation of the drug and device combination in PNH and aHUS indications in the United States and the EU, once this study is completed and 12-month safety data are collected.